eCommons@AKU
Section of Otolaryngology, Head & Neck Surgery

Department of Surgery

March 2005

Olfactory neuroblastoma: a case report and review
of the literature
Shehzad Ghaffar
Aga Khan University, shezad.ghaffar@aku.edu

Iftikhar Salahuddin
Aga Khan University, iftikhar.salahuddin@aku.edu

Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_surg_otolaryngol_head_neck
Part of the Otolaryngology Commons, and the Surgery Commons
Recommended Citation
Ghaffar, S., Salahuddin, I. (2005). Olfactory neuroblastoma: a case report and review of the literature. Ear, Nose, and Throat Journal,
84(3), 150-152.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_surg_otolaryngol_head_neck/79

ORIGINAL SALAHUDDIN
ARTICLE
GHAFFAR,

Olfactory neuroblastoma: A case
report and review of the literature
Shehzad Ghaffar, FCPS (Pak.), FRCS (Ire.); Iftikhar Salahuddin, MD, FRCS (Can.)

Abstract
Malignant tumors of the nasal cavity are rare. We report
the case of an elderly woman who consulted us with a 4year history of progressive nasal obstruction, occasional
epistaxis, facial pain, and watering of the eyes. A diagnosis
of olfactory neuroblastoma was established by histopathology and conﬁrmed by immunohistochemistry. On staging,
the mass was classiﬁed as a Kadish stage B tumor. The
mass was excised via a lateral rhinotomy approach, and
the tumor was peeled away completely from the cribriform
plate with endoscopes. The patient underwent postoperative radiation, and she was free of recurrence at follow-up
15 months later.
Introduction
Malignant tumors of the nasal cavity are rare. Olfactory
neuroblastomas (esthesioneuroblastomas) account for only
6% of these neoplasms.1 Fewer than 1,000 cases have
been reported in the literature since this tumor was ﬁrst
described more than 75 years ago.2 These lesions can be
easily missed because the presenting symptoms mimic those
of benign tumors of the nose. They are often discovered
incidentally during septoplasty or polypectomy.3 Because
olfactory neuroblastomas are so uncommon, few data exist
with respect to optimum management strategies, although
diagnostic and treatment modalities have improved over the
past 2 decades.3-5 Treatment recommendations range from
a minimally invasive approach6 to craniofacial resection
combined with radiotherapy.7
In this article, we report a new case of olfactory neuroblastoma.
Case report
A 67-year-old woman consulted us with a 4-year history
of progressive nasal obstruction, occasional epistaxis,
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facial pain, and watering of the eyes. On rhinoscopy, a
polypoid mass was seen in the roof of her nose; the mass
was not attached to the septum or lateral wall. Her vision
in both eyes was normal, and her eye movements were
unrestricted. Findings on the remainder of the head and
neck examination were unremarkable. The patient had undergone two surgical procedures elsewhere––3 and 1 years
prior to presentation––during which intranasal excision of
the mass had been attempted. These operations ultimately
failed because of an incomplete removal of the mass and
a lack of postoperative radiotherapy.
We performed an intranasal biopsy with local anesthesia, which was completed with minimal bleeding. On
histopathologic analysis, the tumor was identiﬁed as an
olfactory neuroblastoma (ﬁgure 1, A). This ﬁnding was
conﬁrmed by immunohistochemistry, which was positive
for chromogranin, synaptophysin, neuron-speciﬁc enolase,
and neuroﬁlament (ﬁgure 1, B). Computed tomography
(CT) conﬁrmed that the tumor arose from the cribriform
area; no intracranial extension was seen (ﬁgure 2, A). The
ipsilateral anterior and postethmoid cells were involved, but
the maxillary and sphenoid sinuses were free of tumor. The
mass was removed via a lateral rhinotomy approach, and
the tumor was peeled away completely from the cribriform
plate with endoscopes.
Two weeks after surgery, the patient received 6,000 cGy
of radiation in 30 fractions. At follow-up 15 months later,
she was free of recurrence (ﬁgure 2, B).
Discussion
Olfactory neuroblastomas arise from olfactory neuroepithelium, which extends from the roof of the nose to the area of
the superior turbinates and a portion of the nasal septum.7
From there, they can readily extend into the cribriform
plate of the ethmoid sinus. Most of the cases described in
the literature involved adults, but 1 case has been reported
in a child as young as 2 years of age.8
Symptoms. The most common symptoms of olfactory
neuroblastoma are nasal obstruction, epistaxis, and headache (patients with extensive tumors may have orbital
symptoms such as proptosis and excessive lacrimation).9
Because most of these symptoms are similar to those of
benign nasal disease, olfactory neuroblastoma is often
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Figure 1. A: Histopathology demonstrates compact nests of uniform small cells with round basophilic nuclei and scant cytoplasm
(H&E, original magniﬁcation ×20). B: The histopathology ﬁndings are conﬁrmed on immunohistochemistry, which is positive for
chromogranin, synaptophysin, neuron-speciﬁc enolase, and neuroﬁlament.

• More well accepted is the Kadish classiﬁcation system
missed during its early stages and not diagnosed until it
(stages A through C), which is based on the clinical spread
has reached an advanced stage.
Investigation. High-resolution CT and magnetic reso- of the tumor; stage A tumors are conﬁned to the nasal
nance imaging can be used as complementary investigations cavity, stage B lesions involve the sinuses, and stage C
to precisely delineate the extent of the tumor and to deﬁne masses involve the middle cranial fossa and the retrobulbar
the involvement of the cribriform plate, anterior cranial orbit.12 Reservations about the Kadish system are based
fossa, and retromaxillary space. Endoscopic examination on the premise that there are minimal differences in the
is essential for evaluating the extent of the tumor and for biologic behavior of stage A, B, and C tumors. Nevertheless,
tumors in each of these classiﬁcations behave differently
obtaining a biopsy specimen.
Microscopic analysis. The typical histologic appearance with respect to progression and metastasis and, therefore,
of an olfactory neuroblastoma includes the presence of survival patterns are different.
• Biller et al introduced yet another classiﬁcation
characteristic cells separated into nests or compartments
by ﬁbrovascular septae, neuroﬁbrillary intercellular ma- system, which takes into account the size of the primary
trices, and rosette formations. The histologic diagnosis tumor and the presence or absence of regional and distant
is often confounded by the various arrangements of cells metastasis.13
Treatment. Surgical resection is the clear treatment of
packed in sheets and by an architecture that is similar to
many neurogenic tumors. Immunohistochemistry, how- choice, but opinions vary as to its extent. Biller et al recever, can lead to a deﬁnitive
B
diagnosis; this tumor is positive A
for neuroendocrine markers such
as chromogranin, synaptophysin,
neuron-speciﬁc enolase, and protein gene product 9.5.10
Staging. Because malignant
lesions of the nasal cavity are
so rare and because many different histologic types of tumors
abound, no approved classiﬁcation and staging system has been
universally accepted.
• The Hyams classiﬁcation
(grades I through IV) is based
on histologic differentiation; the
grade IV designation is used to
describe undifferentiated sinona- Figure 2. A: Preoperative CT shows the tumor in the cribriform area. B: At follow-up 15
months postoperatively, no sign of recurrence is evident.
sal carcinomas.11
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ommended craniofacial resection of all tumors, regardless
of whether they invade the anterior cranial fossa or are
conﬁned to the nasal roof.13 They advocated resection of
the dura over the cribriform plate, the olfactory bulb, the
entire ethmoid labyrinth, and the anterior and posterior
walls of the frontal sinus.
Preoperative irradiation appears to have no beneﬁcial
effect. Postoperatively, some authors have recommended
radiotherapy only for advanced tumors, while others have
suggested that it should be administered to all patients
regardless of tumor stage.14 As of now, craniofacial resection combined with radiotherapy is considered the gold
standard in the management of these tumors.15
Radical surgery of early lesions (Kadish stages A and
B) is not performed at all centers. The results of transnasal
endoscopic resection followed by radiation have been reported to be comparable to those of craniofacial resection.15
The pursuit of minimally invasive techniques has also led
to the use of endoscopic resection of the tumor combined
with stereotactic irradiation of the frontal skull base with a
gamma-ray knife.6 This approach obviates the need for skin
incisions and midface degloving and avoids the morbidity
associated with conventional radiation therapy (e.g., optic
neuropathy or retinopathy). Neck dissection is indicated
only in the presence of nodes; elective dissection appears
to be unnecessary.
The role of induction chemotherapy or concurrent
chemoradiation therapy has not been deﬁned. We know
that olfactory neuroblastoma is chemosensitive and responsive to platinum-based agents,16,17 but chemotherapy
is currently reserved for unresectable or recurrent tumors
and for metastases.
Metastasis. Olfactory neuroblastomas have the potential
to spread regionally. Neck metastasis can occur early in
the disease or many years later. Rinaldo et al reviewed 320
cases at 15 centers and found that the incidence of both
synchronous and metachronous neck metastases varied
greatly, ranging from 5 to 100% (mean: 23.4%).10 As is true
for most head and neck cancers, cervical lymphadenopathy
augurs poorly and increases the risk of distant metastasis,
most often to bones.18
Recurrence. Despite aggressive therapy, recurrence can
develop soon after treatment or even several years later.
Researchers at the Mayo Clinic reported that 42% of local
recurrences developed within 5 years postoperatively and
that 1 case recurred as late as 10 years after surgery.19 In
a review of 40 patients, Eden et al reported a recurrence
rate of 55%; two-thirds of these patients had locoregional
disease, and 39% of them developed recurrences within
5 years of combined-modality (surgery plus radiation)
treatment.20 Finally, researchers at the University of Iowa
reported 5- and 10-year actuarial disease-free survival rates
of 56 and 42%, respectively.4
In conclusion, olfactory neuroblastoma requires ag152

gressive surgical resection and radiation therapy. Patients must be followed carefully with the understanding
that locoregional recurrences are common and may arise
several years after treatment. The prognosis for long-term
survival is poor.
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